IP Library › Granted Patent US 12,312,296
Granted Patent B2
US 12,312,296 · App. 17/803,951 · Granted May 27, 2025

Substituted piperazines as disrupters of AB42 oligomer formation

Inventors: Ambuj K. Singh (Santa Barbara, CA); Christian A. Lang (Santa Barbara, CA)
Assignee: ACELOT, INC.
C07C233/43A61K31/131A61K31/135A61K31/137C07C211/27C07C211/28C07C211/29C07C217/60C07C223/02C07C271/18C07D207/06C07D295/135C07D295/15C07D319/18C07D413/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,312,296
App. No.
17/803,951
Granted
May 27, 2025
Kind
B2
Abstract

Described herein, inter alia, are certain substituted piperazines, for example, having the Formula 182, and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of Aβ42 oligomers in a subject. It further provides a method of reducing formation of or disrupting Aβ42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.

Claims (67)

1. A method for reducing formation of amyloid beta 42 (Aβ42) oligomers or disrupting formation of amyloid beta 42 (Aβ42) oligomers in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of Formula 182:

or a pharmaceutically acceptable salt thereof,

wherein:

(i) R 60 is a branched or unbranched (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is substituted with one aryl substituent and optionally further substituted with one or more substituents independently selected from the group consisting of halogen, C(O)R, C(O)NRR′, C(O)OH, C(O)O (alkyl), NRR′, O(alkyl), O(aryl), saturated cyclic hydrocarbon, unsaturated cyclic hydrocarbon, and aryl; or

(ii) R 60 is a branched or unbranched (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is substituted with one substituent independently selected from the group consisting of C(O)alkyl, C(O)NRR′, C(O)OH, and C(O)O (alkyl), and optionally further substituted with one or more substituents independently selected from the group consisting of halogen, C(O)R, C(O)NRR′, C(O)OH, C(O)O (alkyl), NRR′, OH, O(alkyl), O(aryl), saturated cyclic hydrocarbon, unsaturated cyclic hydrocarbon, and aryl; or

(iii) R 60 is a branched or unbranched (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is substituted with one aryl substituent, one substituent independently selected from the group consisting of C(O)alkyl, C(O)NRR′, C(O)OH, and C(O)O (alkyl), and optionally further substituted with one or more substituents independently selected from the group consisting of halogen, C(O)R, C(O)NRR′, C(O)OH, C(O)O (alkyl), NRR′, OH, O(alkyl), O(aryl), saturated cyclic hydrocarbon, unsaturated cyclic hydrocarbon, and aryl;

R 62 is hydrogen, halogen, or (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is optionally substituted with one or more independently selected substituents;

R 63 is hydrogen, halogen, or (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is optionally substituted with one or more independently selected substituents;

R 64 is hydrogen, halogen, or (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is optionally substituted with one or more independently selected substituents;

R 65 is hydrogen, halogen, or (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is optionally substituted with one or more independently selected substituents;

R 66 is hydrogen, halogen, or (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is optionally substituted with one or more independently selected substituents;

R 67 is hydrogen, halogen, or (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is optionally substituted with one or more independently selected substituents;

R 68 is hydrogen, halogen, or (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is optionally substituted with one or more independently selected substituents;

R 69 is hydrogen, halogen, or (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is optionally substituted with one or more independently selected substituents;

R 80 is hydrogen, halogen, (C 1 -C 6 ) alkyl, or O(C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is optionally substituted with one or more independently selected substituents;

R 81 is hydrogen, halogen, or (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is optionally substituted with one or more independently selected substituents;

R 82 is OH, O(C 1 -C 6 ) alkyl, or O(aryl);

R 83 is hydrogen, halogen, or (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is optionally substituted with one or more independently selected substituents;

R 84 is hydrogen, halogen, or (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is optionally substituted with one or more independently selected substituents;

each R is independently hydrogen or alkyl, wherein each alkyl is optionally and independently substituted with one or more independently selected substituents;

each R′ is independently hydrogen or alkyl, wherein each alkyl is optionally and independently substituted with one or more independently selected substituents; and

wherein each optional substituent for each (C 1 -C 6 ) alkyl of R 62 , R 63 , R 64 , R 65 , R 66 , R 67 , R 68 , R 69 , R 80 , R 81 , R 83 , and R 84 is independently selected from the group consisting of h alogen, C(O)R, C(O) NRR′, C(O)OH, C(O)O alkyl), NRR′, OH, O(alkyl), OC(O)R, O(aryl), saturated cyclic hydrocarbon, and unsaturated cyclic hydrocarbon.

2. The method of claim 1 , wherein:

(a) the Aβ42 oligomer is a hexamer or dodecamer; and

(b) formation of the hexamer or dodecamer is reduced; or

(c) the amount of the hexamer or dodecamer is reduced.

3. The method of claim 1 , wherein the subject is at risk for developing Alzheimer's disease (AD).

4. The method of claim 1 , wherein the subject is genetically predisposed to Alzheimer's disease (AD).

5. The method of claim 1 , wherein the subject has the gene for early onset familial Alzheimer's disease (AD).

6. The method of claim 1 , wherein the subject is diagnosed with Alzheimer's disease (AD).

7. The method of claim 1 , wherein R 60 is a branched or unbranched (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is substituted with one aryl substituent and optionally further substituted with one or more substituents independently selected from the group consisting of C(O)R, C(O)NRR′, C(O)OH, C(O)O (alkyl), and NRR′.

8. The method of claim 1 , wherein R 60 is a branched or unbranched (C 1 -C 6 ) alkyl, wherein the (C 1 -C 6 ) alkyl is substituted with one substituent independently selected from the group consisting of C(O) alkyl, C(O)NRR′, C(O)OH, and C(O)O (alkyl), and optionally further substituted with one or more substituents independently selected from the group consisting of saturated cyclic hydrocarbon, unsaturated cyclic hydrocarbon, and aryl.

9. The method of claim 1 , wherein R 60 is:

10. The method of claim 1 , wherein:

R 62 is hydrogen or unsubstituted (C 1 -C 6 ) alkyl;

R 63 is hydrogen or unsubstituted (C 1 -C 6 ) alkyl;

R 68 is hydrogen or unsubstituted (C 1 -C 6 ) alkyl; and

R 69 is hydrogen or unsubstituted (C 1 -C 6 ) alkyl.

11. The method of claim 1 , wherein:

R 62 is hydrogen;

R 63 is hydrogen;

R 68 is hydrogen; and

R 69 is hydrogen.

12. The method of claim 1 , wherein:

R 64 is hydrogen or unsubstituted (C 1 -C 6 ) alkyl;

R 65 is hydrogen or unsubstituted (C 1 -C 6 ) alkyl;

R 66 is hydrogen or unsubstituted (C 1 -C 6 ) alkyl; and

R 67 is hydrogen or unsubstituted (C 1 -C 6 ) alkyl.

13. The method of claim 1 , wherein:

R 64 is hydrogen;

R 65 is hydrogen;

R 66 is hydrogen; and

R 67 is hydrogen.

14. The method of claim 1 , wherein:

R 80 is hydrogen, halogen, or unsubstituted (C 1 -C 6 ) alkyl;

R 81 is hydrogen, halogen, or unsubstituted (C 1 -C 6 ) alkyl;

R 83 is hydrogen, halogen, or unsubstituted (C 1 -C 6 ) alkyl; and

R 84 is hydrogen, halogen, or unsubstituted (C 1 -C 6 ) alkyl.

15. The method of claim 1 , wherein:

R 80 is hydrogen;

R 81 is hydrogen;

R 83 is hydrogen; and

R 84 is hydrogen.

16. The method of claim 1 , wherein R 82 is OH or O(C 1 -C 6 ) alkyl.

17. The method of claim 1 , wherein R 82 is OH.

18. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2023
From: SINGH, AMBUJ K.; LANG, CHRISTIAN A.
To: ACELOT, INC.
Reel/Frame 064473/0033 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2023
From: SINGH, AMBUJ K.; LANG, CHRISTIAN A.
To: ACELOT, INC.
Reel/Frame 064473/0047 →
Continuity (4)
Continuation 16836835 · Mar 31, 2020
Division 16350344 · Nov 5, 2018
Provisional Application 62707516 · Nov 6, 2017
Related Publication 20230331658A1 · Oct 19, 2023
References Cited (71)
US 6124296A · Schnorrenberg et al. · 2000 [cited by applicant]
US 6303610B1 · Johnson et al. · 2001 [cited by applicant]
US 8236806B2 · Kong et al. · 2012 [cited by applicant]
US 9500640B2 · Wang · 2016 [cited by examiner]
US 10703711B2 · Singh et al. · 2020 [cited by applicant]
US 11827582B2 · Singh et al. · 2023 [cited by applicant]
US 20110251212A1 · Masui et al. · 2011 [cited by applicant]
US 20120027699A1 · Rosa et al. · 2012 [cited by applicant]
US 20130143924A1 · Ducray et al. · 2013 [cited by applicant]
US 20200223788A1 · Singh et al. · 2020 [cited by applicant]
US 20210052519A1 · Singh et al. · 2021 [cited by applicant]
AU 2004309280A1 · 2005 [cited by applicant]
CN 1865260A · 2006 [cited by applicant]
EP 0761219A1 · 1997 [cited by applicant]
EP 2163541A1 · 2010 [cited by applicant]
FR 903296 · 1945 [cited by applicant]
WO WO98017651A1 · 1998 [cited by applicant]
WO WO02078693A2 · 2002 [cited by applicant]
WO WO02078693A3 · 2002 [cited by applicant]
WO WO2005063705A1 · 2005 [cited by applicant]
WO WO2008147314A1 · 2008 [cited by applicant]
WO WO2009006437A1 · 2009 [cited by applicant]
WO WO2009051661A2 · 2009 [cited by applicant]
WO WO2010074588A2 · 2010 [cited by applicant]
WO WO2012013418 · 2012 [cited by applicant]
WO WO2012013716A1 · 2012 [cited by applicant]
WO WO2013059582A2 · 2013 [cited by applicant]
WO WO2013103973A1 · 2013 [cited by applicant]
WO WO2013161993A1 · 2013 [cited by applicant]
WO WO2015157382A1 · 2015 [cited by examiner]
WO WO2019089066A1 · 2019 [cited by applicant]
CAS Registry Database, RN: 32121-39-4, entered STN: Nov. 16, 1984 and RN: 690991-57-2, entered STN: Jun. 9, 2004, accessed on Jan. 16, 2024. [cited by examiner]
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205. [cited by examiner]
Hackam, et al. JAMA, 296(14), 2006, 1731-1732. [cited by examiner]
Guo, H. et al. (Oct. 16, 2010). “Acidic ionic liquid [NMP]H2PO4 as dual solvent-catalyst for synthesis of β-alkoxyketones by the oxa-Michael addition reactions,” [cited by applicant]
Sakura, et al. (Jun. 20, 1972). “Catalytic Hydrogenolyses of Benzylidene Compounds Bound to Two Oxygens, Two Nitrogens and Both Oxygen and Nitrogen,” [cited by applicant]
Zhou, Y-H. et al. (2008). “Ester hydrolysis by a cyclodextrin dimer catalyst with a metallophenanthroline linking group,” [cited by applicant]
Reyes, A. et al. (Jan. 19, 1999). “Convenient route for the preparation of C2-symmetric (+)-(2R,3R)- and (−)-(2S,3S)-2,3-diphenylaziridine” [cited by applicant]
Yuan, M-L. et al. (2014). “Enantioselective Synthesis of Chiral 1,2-Amino Alcohols via Asymmetric Hydrogenation of α-Amino Ketones with Chiral Spiro Iridium Catalysts,” [cited by applicant]
Yan, T. et al., (Dec. 3, 2015). “Benzylamines via Iron-Catalysed Direct Amination of Benzyl Alcohols” [cited by applicant]
Proshin, A.N. et al. (Sep. 27, 2016). “Tetrasubstituted thiuronium salts as multitarget compounds affecting brain NMDA and AMPA receptors,” [cited by applicant]
Petersen, I.N. et al., (Nov. 1, 2016). “Convergent 18F-labeling and evaluation of N-benzyl-phenethylamines as 5-HT2A receptor PET ligands,” [cited by applicant]
Pubchem, Substrate Record for SID 319065898, Available Date: Nov. 25, 2016 [retrieved on Feb. 11, 2019 from the Internet:https://pubchem.ncbi.nlm.nih.gov/substance/319065898] entire doc. [cited by applicant]
Pubchem, Substrate Record for SID 262562287, Available Date: Dec. 10, 2015 [retrieved on Dec. 20, 2018 from the Internet:https://pubchem.ncbi.nlm.nih.gov/substance/262562287] entire doc. [cited by applicant]
Pubchem, Substrate Record for SID 120374932, Available Date: Apr. 5, 2011 [retrieved on Dec. 20, 2018 from the Internet:https://pubchem.ncbi.nlm.nih.gov/substance/120374932] entire doc. [cited by applicant]
Benilova, I. et al. (Jan. 29, 2012). “The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes,” [cited by applicant]
Reiman, E.M. et al. (2011). “Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments,” [cited by applicant]
Dahlgren, K.N. et al. (Aug. 30, 2002). “Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability,” [cited by applicant]
Hayden, E.Y. et al. (Nov. 29, 2013). “Amyloid β-protein oligomers and Alzheimer's disease,” [cited by applicant]
Meng, F. et al. (Sep. 21, 2010). “The flavanol (−)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxi… [cited by applicant]
Wu, J.W. et al. (Feb. 26, 2010). “Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation,” [cited by applicant]
Ladiwala, A.R.A. et al. (Dec. 4, 2012). “Rational design of potent domain antibody inhibitors of amyloid fibril assembly,” [cited by applicant]
Lee, J. et al. (Jun. 25, 2014). “Tandem Synthesis of Amides and Secondary Amines from Esters with Primary Amines under Solvent-Free Conditions,” [cited by applicant]
Database Registry RN 1209424-09-8, entered STN Mar. 12, 2010, 1 page. [cited by applicant]
CAS Registry No. 103-49-1, STN Entry Date Nov. 16, 1984, 11 pages. [cited by applicant]
CAS Registry No. 199982-20-2, STN Entry Date Jan. 20, 1998, 5 pages. [cited by applicant]
CAS Registry No. 1310299-45-6, STN Entry Date Jun. 24, 2011, 5 pages. [cited by applicant]
CAS Registry No. 133715-32-9, STN Entry Date May 10, 1991, 5 pages. [cited by applicant]
CAS Registry No. 1310313-44-0, STN Entry Date Jun. 24, 2011, 5 pages. [cited by applicant]
CAS Registry No. 1176493-40-5, STN Entry Date Aug. 27, 2009, 5 pages. [cited by applicant]
CAS Registry No. 1175705-15-3, STN Entry Date Aug. 25, 2009, 5 pages. [cited by applicant]
CAS Registry No. 1209424-09-8, STN Entry Date Mar. 12, 2010, 5 pages. [cited by applicant]
CAS Registry No. 1019499-03-6, STN Entry Date May 6, 2008, 5 pages. [cited by applicant]
CAS Registry No. 893583-01-2, STN Entry Date Jul. 17, 2006, 5 pages. [cited by applicant]
CAS Registry No. 1498812-38-6, STN Entry Date Dec. 19, 2013, 5 pages. [cited by applicant]
CAS Registry No. 1310080-47-7, STN Entry Date Jun. 23, 2011, 5 pages. [cited by applicant]
CAS Registry No. 763054-53-1, STN Entry Date Oct. 15, 2004, 5 pages. [cited by applicant]
Piplani, P. et al. (Jun. 2015). “Design and synthesis of newer potential 4-(N-acetylamino)phenol derived piperazine derivatives as potential cognition enhancers,” [cited by applicant]
Abdullah, A.H et al. (2016). “Synthesis and antibacterial activity of N1-(carbazol-3- yl)amidrazones incorporating piperazines and related congeners,” Z. Naturforsch 71(8)b:857- 867. [cited by applicant]
Al-Rawashdeh, B.H et al. (2017). “Synthesis and Properties of Some N-(2,3- Dihydrophthalazin-5-yl) amidrazones Incorporating Piperazines and Related Congeners,” Asian J Chem 29(3):605-608. [cited by applicant]
Musameh, S.A et al. (2016). “Synthesis and Biological Activity of Some New N1-(4- oxoquinolin-6-yl) amidrazones,” Letters in Organic Chemistry 13(2): 120-126. [cited by applicant]